


Superior Weight Loss and Glycemic Control Compared to Insulin Therapy

EXENATIDE ONCE WEEKLY

DURATION 3 Top-line Results

- > Exenatide once weekly delivered statistically significant improvements in glycemic control and body weight
- > Evaluable Patients treated with exenatide once weekly experienced A1c reductions of 1.5% compared to 1.3% for Lantus®
- > Results support superiority of exenatide once weekly even though Lantus was administered in variable doses determined by patient blood sugar levels




Compelling Evidence Supporting Superiority Relative to Commonly Prescribed Oral Agents

EXENATIDE ONCE WEEKLY

DURATION 2 Results

> Exenatide once weekly achieved statistically significant HbA1c and weight reductions relative to Januvia™ (sitagliptin) or Actos® (pioglitazone)

Change in HbA1c % at 26 Weeks vs. maximum doses of Januvia or Actos



Change in weight at 26 Weeks vs. maximum doses of Januvia or Actos

